This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (18)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ronald Bleday, MD; Michael J. Weiss, PhD; Ronald R. Salem, MD; Richard E. Wilson, MD; Lan Bo Chen, PhD; Glenn Steele, Jr, MD

Arch Surg. 1986;121(11):1272-1275.

Abstract
• In searching for a new approach to the systemic treatment of colorectal carcinoma, we have observed that certain lipophilic cationic compounds are accumulated and retained for a significantly longer period in the mitochondria of living carcinoma cells than in normal cells or sarcoma cells. We report the in vivo therapeutic effect of one of these compounds, dequalinium chloride, on the W163 rat colon carcinoma isograft, which grows rapidly in Wistar/Furth rats after primary tumor implantation, and which recurs rapidly after primary tumor resection. In the primary transplant model, tumors were implanted, and daily dequalinium chloride treatments were begun the following day in doses ranging from 1 to 10 mg/kg. In the recurrence model, isografts were implanted, allowed to grow for one week, and then all gross tumor was resected. Dequalinium chloride was administered in varying daily doses starting the day after resection. In both models, tumor was removed on day 11 after implantation or resection. At sublethal doses, dequalinium chloride significantly inhibited primary tumor growth to 60% that of controls and recurrent tumor growth to 50% that of controls. We propose that this unique biologic approach of targeting carcinoma mitochondria with lipophilic cationic compounds may provide a major new opportunity for treating colorectal carcinoma.

(Arch Surg 1986;121:1272-1275)

Author Affiliations
From the Laboratory of Cancer Biology, Department of Surgery, New England Deaconess Hospital (Drs Bleday, Weiss, Salem, and Steele), the Department of Surgery, Brigham and Women's Hospital (Drs Bleday and Wilson), and the Department of Pathology, Division of Cell Growth and Regulation, Dana-Farber Cancer Institute, Harvard Medical School (Dr Chen), Boston.

Footnotes
Accepted for publication July 31, 1986.

Read before the 39th Annual Meeting of the Society of Surgical Oncology, Washington, DC, May 13, 1986.

Reprint requests to Department of Surgery, New England Deaconess Hospital, 110 Francis St, Boston, MA 02115 (Dr Steele).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Potential Use of Cetrimonium Bromide as an Apoptosis-Promoting Anticancer Agent for Head and Neck Cancer
Ito et al.
Mol. Pharmacol. 2009;76:969-983.
ABSTRACT | FULL TEXT